FDA approves Eohilia for eosinophilic esophagitis
The U.S. Food and Drug Administration has approved Takeda's Eohilia (budesonide oral suspension) as the first and only oral treatment for eosinophilic esophagitis (EoE).
Feb 19, 2024
0
1
The U.S. Food and Drug Administration has approved Takeda's Eohilia (budesonide oral suspension) as the first and only oral treatment for eosinophilic esophagitis (EoE).
Feb 19, 2024
0
1
Researchers at Ghent University Hospital, Ghent University, and VIB-UGent Center for Inflammation Research, show that antibody therapy can be effective against erosive hand osteoarthritis. Using the antibody denosumab leads ...
Feb 15, 2024
0
49
For patients with relapsing multiple sclerosis, the anti-CD40L monoclonal antibody frexalimab has a favorable effect on the number of new gadolinium-enhancing T1-weighted lesions, according to a study published in the Feb. ...
Feb 15, 2024
0
0
For patients with acute ischemic stroke secondary to large-vessel occlusion (LVO) undergoing endovascular thrombectomy, adjuvant low-dose methylprednisolone does not improve the degree of overall disability, according to ...
Feb 14, 2024
0
0
For patients with moderate-to-severe plaque psoriasis, the interleukin-23-receptor antagonist peptide JNJ-77242113 shows greater efficacy than placebo, according to a study published in the Feb. 8 issue of the New England ...
Feb 8, 2024
0
0
A study from the University of Oklahoma College of Medicine at OU Health Sciences shows that stimulating the body's longest nerve through a clip on the ear significantly lessens the woozy symptoms of POTS, or postural tachycardia ...
Feb 5, 2024
0
54
Treatment with N-acetyl-L-leucine (NALL) for 12 weeks yields better neurological status than placebo among patients with genetically confirmed Niemann-Pick disease type C, according to a study published in the Feb. 1 issue ...
Feb 1, 2024
0
0
For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months, according to a study presented at the ...
Feb 1, 2024
0
1
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) for the treatment of pediatric patients (aged one to 11 years) with eosinophilic esophagitis (EoE).
Jan 30, 2024
0
7
For extremely preterm infants, the risk for death or moderate or severe bronchopulmonary dysplasia is not significantly lower among those receiving early treatment for patent ductus arteriosus (PDA) with ibuprofen versus ...
Jan 25, 2024
0
0